Q-omics provides the consensus-scored LINC02228 profile across patient tissues and cancer cell-line models. LINC02228 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC02228 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, LINC02228 RNA expression shows 10,758 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, HNSC, and THYM as cancer lineages where LINC02228 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02228 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02228 survival associations across molecular data types. LINC02228 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02228 RNA expression–survival associations across cancer types. High LINC02228 expression shows unfavorable associations in COAD, UCEC, KICH, MESO and LIHC, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC02228 RNA expression.
This table summarizes LINC02228 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02228. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02228 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, LIHC, COAD and LUSC. The HNSC box plot shows higher LINC02228 RNA expression in tumor versus normal tissue (log2 FC = +0.115, t-test p = .001).
This table shows molecular features associated with LINC02228 in patient tissues and cancer cell lines. In patient samples, LINC02228 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
